FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022043510> ?p ?o ?g. }

• W2022043510 endingPage "1002" @default.
• W2022043510 startingPage "997" @default.
• W2022043510 abstract "1 The concentration of the astrocytic marker, glial fibrillary acidic protein (GFAP) was quantitated by immunoblotting (western blotting) in the rat brain after treatment with various imidazoline drugs and other agents. 2 Chronic (7 days) but not acute (1 day) treatment with the imidazoline drugs, cirazoline (1 mg kg−1, i.p.) and idazoxan (10 mg kg−1, i.p.), but not with the structurally related α2-adrenoceptor antagonists, RX821002 (2-methoxy idazoxan) (10 mg kg−1, i.p.) and efaroxan (10 mg kg−1, i.p.), markedly increased (45%) GFAP immunoreactivity in the rat cerebral cortex. Chronic treatment (7 days) with yohimbine (10 mg kg−1, i.p.), a non-imidazoline α2-adrenoceptor antagonist, did not significantly modify GFAP immunoreactivity in the cerebral cortex. 3 Chronic treatment (7 days) with cirazoline and idazoxan did not alter the density of brain monoamine oxidase (MAO)-B sites labelled by [3H]-Ro 19–6327 (lazabemide), another relevant astroglial marker. Moreover, these imidazoline drug treatments did not modify the levels of α-tubulin in the cerebral cortex. These negative results reinforced the specificity of the effects of imidazoline drugs on GFAP. 4 Irreversible inactivation of brain α2-adrenoceptors (and other neurotransmitters receptors) after treatment with an optimal dose of the peptide-coupling agent EEDQ (1.6 mg kg−1, i.p., for 6–24 h) did not alter GFAP immunoreactivity in the cerebral cortex. These results further disproved the involvement of these receptors on astroglial cells in the tonic control of GFAP levels. 5 The binding of [3H]-idazoxan in the presence of 10−6 m (–)-adrenaline was used to quantitate in parallel I2-imidazoline preferring sites in the rat brain after the same treatments. Chronic treatment (7 days) with cirazoline and idazoxan, but not with RX821002, efaroxan or yohimbine, significantly increased (25%) the density of I2-sites in the cerebral cortex. The up-regulation of I2-sites induced by cirazoline was not observed in the liver, a tissue that also expresses I2-sites but lacks glial cells. 6 A strong correlation (r = 0.97) was found when the mean percentage changes in GFAP immunoreactivity were related to the mean percentage changes in I2 imidazoline sites after the various drug treatments. 7 Together the results suggest a direct physiological function of glial I2-imidazoline preferring sites in the regulation of GFAP levels." @default.
• W2022043510 created "2016-06-24" @default.
• W2022043510 creator A5019545057 @default.
• W2022043510 creator A5044317538 @default.
• W2022043510 creator A5065044721 @default.
• W2022043510 creator A5087406461 @default.
• W2022043510 date "1994-04-01" @default.
• W2022043510 modified "2023-10-18" @default.
• W2022043510 title "The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain" @default.
• W2022043510 cites W1547548853 @default.
• W2022043510 cites W159198934 @default.
• W2022043510 cites W1775749144 @default.
• W2022043510 cites W1936808599 @default.
• W2022043510 cites W1952790402 @default.
• W2022043510 cites W1963860273 @default.
• W2022043510 cites W1965718695 @default.
• W2022043510 cites W1970862254 @default.
• W2022043510 cites W1976368911 @default.
• W2022043510 cites W1980115830 @default.
• W2022043510 cites W1985302689 @default.
• W2022043510 cites W1992559673 @default.
• W2022043510 cites W1994857072 @default.
• W2022043510 cites W1995528771 @default.
• W2022043510 cites W1997607044 @default.
• W2022043510 cites W1999691892 @default.
• W2022043510 cites W2001727865 @default.
• W2022043510 cites W2011843754 @default.
• W2022043510 cites W2027721538 @default.
• W2022043510 cites W2029023869 @default.
• W2022043510 cites W2033067482 @default.
• W2022043510 cites W2036199324 @default.
• W2022043510 cites W2043813981 @default.
• W2022043510 cites W2044909621 @default.
• W2022043510 cites W2055390759 @default.
• W2022043510 cites W2055943620 @default.
• W2022043510 cites W2060927932 @default.
• W2022043510 cites W2062841992 @default.
• W2022043510 cites W2066510319 @default.
• W2022043510 cites W2075990478 @default.
• W2022043510 cites W2076099286 @default.
• W2022043510 cites W2080493596 @default.
• W2022043510 cites W2083953235 @default.
• W2022043510 cites W2087296926 @default.
• W2022043510 cites W2090898235 @default.
• W2022043510 cites W2094775681 @default.
• W2022043510 cites W2095519131 @default.
• W2022043510 cites W2128635872 @default.
• W2022043510 cites W2131655003 @default.
• W2022043510 cites W2137864613 @default.
• W2022043510 cites W2142456895 @default.
• W2022043510 cites W2151878943 @default.
• W2022043510 cites W2248766863 @default.
• W2022043510 cites W2252465426 @default.
• W2022043510 cites W2265790923 @default.
• W2022043510 cites W2318073724 @default.
• W2022043510 cites W4293247451 @default.
• W2022043510 doi "https://doi.org/10.1111/j.1476-5381.1994.tb14842.x" @default.
• W2022043510 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1910123" @default.
• W2022043510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8032628" @default.
• W2022043510 hasPublicationYear "1994" @default.
• W2022043510 type Work @default.
• W2022043510 sameAs 2022043510 @default.
• W2022043510 citedByCount "64" @default.
• W2022043510 countsByYear W20220435102012 @default.
• W2022043510 countsByYear W20220435102014 @default.
• W2022043510 countsByYear W20220435102015 @default.
• W2022043510 countsByYear W20220435102018 @default.
• W2022043510 countsByYear W20220435102019 @default.
• W2022043510 countsByYear W20220435102020 @default.
• W2022043510 countsByYear W20220435102021 @default.
• W2022043510 countsByYear W20220435102022 @default.
• W2022043510 countsByYear W20220435102023 @default.
• W2022043510 crossrefType "journal-article" @default.
• W2022043510 hasAuthorship W2022043510A5019545057 @default.
• W2022043510 hasAuthorship W2022043510A5044317538 @default.
• W2022043510 hasAuthorship W2022043510A5065044721 @default.
• W2022043510 hasAuthorship W2022043510A5087406461 @default.
• W2022043510 hasBestOaLocation W20220435101 @default.
• W2022043510 hasConcept C123605464 @default.
• W2022043510 hasConcept C126322002 @default.
• W2022043510 hasConcept C134018914 @default.
• W2022043510 hasConcept C170493617 @default.
• W2022043510 hasConcept C185592680 @default.
• W2022043510 hasConcept C204232928 @default.
• W2022043510 hasConcept C2776885963 @default.
• W2022043510 hasConcept C2777542381 @default.
• W2022043510 hasConcept C2777676773 @default.
• W2022043510 hasConcept C2780495277 @default.
• W2022043510 hasConcept C2780648677 @default.
• W2022043510 hasConcept C2780939551 @default.
• W2022043510 hasConcept C2781041448 @default.
• W2022043510 hasConcept C529278444 @default.
• W2022043510 hasConcept C71924100 @default.
• W2022043510 hasConcept C98274493 @default.
• W2022043510 hasConceptScore W2022043510C123605464 @default.
• W2022043510 hasConceptScore W2022043510C126322002 @default.
• W2022043510 hasConceptScore W2022043510C134018914 @default.
• W2022043510 hasConceptScore W2022043510C170493617 @default.

• next